Persistent negative symptoms in schizophrenia: An overview

Schizophrenia Bulletin

Volumn 33, Issue 4, 2007, Pages 1013-1022

  Buchanan, Robert W ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Deficit syndrome; Negative symptoms; Persistent negative symptoms; Pharmacological treatment; Schizophrenia

Indexed keywords

AMISULPRIDE; CLOZAPINE; CYCLOSERINE; GLYCINE; HALOPERIDOL; MONOAMINE OXIDASE INHIBITOR; OLANZAPINE; SELEGILINE;

ADD ON THERAPY; AFFECT; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; EMOTION; EXTRAPYRAMIDAL SYMPTOM; FUNCTIONAL DISEASE; HUMAN; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD DISORDER; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOTYPAL PERSONALITY DISORDER; SOCIAL LIFE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW;

AFFECT; BRIEF PSYCHIATRIC RATING SCALE; DISEASE PROGRESSION; EXPRESSED EMOTION; HUMANS; PREVALENCE; SCHIZOPHRENIA;

EID: 34547666657     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbl057     Document Type: Conference Paper

References (72)

1. Kraepelin E. Dementia Praecox and Paraphrenia. Barclay RM, trans. New York, NY: RE Krieger; 1919. [Reprint 1971].
2. Bleuler E. Dementia Praecox, or the Group of Schizophrenias.- Zinkin J, trans-ed. New York, NY: International Universities Press; 1908.
3. Strauss JS, Carpenter WT Jr, Bartko JJ. The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr Bull. 1974;11:61-69.
4. Crow TJ. Molecular pathology of schizophrenia: more than one disease process? Br Med J. 1980;280:66-68.
5. Crow TJ. Two-syndrome concept: origins and current status. Schizophr Bull. 1985;11:471-486.
6. Andreasen NC. Negative symptoms of schizophrenia: definition and reliability. Arch Gen Psychiatry. 1982;43:136-144.
7. Andreasen NC, Olsen S. Negative v positive schizophrenia. Definition and validation. Arch Gen Psychiatry. 1982;39:789-794.
8. Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT Jr. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry. 2001;58:165-171.
9. Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry. 2005;162:495-506.
10. Kurtz MM, Moberg JP, Ragland JD, Gur RC, Gur RE. Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: a 1- and 4-year prospective study. Schizophr Bull. 2005;31:167-174.
11. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
12. Andreasen NC. The Scale for Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa; 1984.
13. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
14. Goldberg SC. Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophr Bull. 1985;11:453-456.
15. Meltzer HY, Sommers AA, Luchins DJ. The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia. J Clin Psychopharmacol. 1986;6:329-338.
16. Kane J, Honigfeld G, Singer J, Meltzer HY, Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.
17. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151:825-835.
18. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997;154:457-765.
19. Tandon R, Goldman R, DeQuardo JR, Goldman M, Perez M, Jibson M. Positive and negative symptoms covary during clozapine treatment in schizophrenia. J Psychiatr Res. 1993;27:341-347.
20. Miller DD, Perry PJ, Cadoret RJ, Andreasen NC. Clozapine's effect on negative symptoms in treatment-refractory schizophrenics. Compr Psychiatry. 1994;35:8-15.
21. Carpenter WT Jr. Clinical constructs and therapeutic discovery. Schizophr Res. 2004;72:69-73.
22. Carpenter WT Jr, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry. 1988;145:578-583.
23. Buchanan RW, Brandes M, Breier A. Treating negative symptoms: pharmacological strategies. In: Breier A, ed. The New Pharmacotherapy of Schizophrenia. Washington, DC: American Psychiatric Press; 1996:179-204.
24. Carpenter WT Jr, Heinrichs DW, Alphs LD. Treatment of negative symptoms. Schizophr Bull. 1985;11:440-452.
25. Kelley ME, van Kammen DP, Allen DN. Empirical validation of primary negative symptoms: independence from effects of medication and psychosis. Am J Psychiatry. 1999;156:406-411.
26. Tandon R, Jibson MD, Taylor SF, DeQuadro JR. Conceptual models of the relationship between positive and negative symptoms. In: Shiqui SL, Nasrallah HA, eds. Contemporary Issues in the Treatment of Schizophrenia. Washington, DC: American Psychiatric Press; 1995:109-124.
27. Tandon R, DeQuardo JR, Taylor SF, et al. Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome. Schizophr Res. 2000;45:191-201.
28. Carpenter WT Jr, Buchanan RW, Kirkpatrick B, Tamminga C, Wood F. Strong inference, theory testing, and the neuroanatomy of schizophrenia. Arch Gen Psychiatry. 1993;50:825-831.
29. Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT Jr. The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res. 1989;30:119-123.
30. Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32:214-249.
31. Bottlender R, Wegner U, Wittmann J, Strauss A, Moller HJ. Deficit syndromes in schizophrenic patients 15 years after their first hospitalisation: preliminary results of a follow-up study. Eur Arch Psychiatry Clin Neurosci. 1999;249 (Suppl 4):27-36.
32. Harris MJ, Jeste DV, Krull A, Montague J, Heaton RK. Deficit syndrome in older schizophrenic patients. Psychiatry Res. 1991;39:285-292.
33. Mayerhoff DI, Loebel AD, Alvir JM, et al. The deficit state in first-episode schizophrenia. Am J Psychiatry. 1994;151:1417-1422.
34. Peralta V, Cuesta MJ. The deficit syndrome of the psychotic illness. A clinical and nosological study. Eur Arch Psychiatry Clin Neurosci. 2004;254:165-171.
35. Kirkpatrick B, Ross DE, Walsh D, Karkowski L, Kendler KS. Family characteristics of deficit and nondeficit schizophrenia in the Roscommon family study. Schizophr Res. 2000;45:57-64.
36. Ross DE, Kirkpatrick B, Karkowski LM, et al. Sibling correlation of deficit syndrome in the Irish study of high-density schizophrenia families. Am J Psychiatry. 2000;157:1071-1076.
37. Andreasen NC, Black DW. Introductory Textbook of Psychiatry. 3rd ed. Washington, DC: American Psychiatric Press; 2001.
38. Axelrod BN, Goldman RS, Woodard JL, Alphs LD. Factor structure of the negative symptom assessment. Psychiatry Res. 1994;52:173-179.
39. Andreasen NC. The Scale for Assessment of Positive Symptoms (SAPS). Iowa City: University of Iowa; 1984.
40. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res. 1990;3:247-251.
41. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
42. Chouinard G, Ross Chouinard A, Annable L, Jones BD. Extrapyramidal Symptom Rating Scale [ESRS] (1980). In: Sajatovic M, Ramirez LF, eds. Rating Scales in Mental Health. Hudson, OH: Lexi-Comp; 2001:209-213.
43. Alphs LD, Summerfelt A, Lann H, Muller RJ. The negative symptom assessment: a new instrument to assess negative symptoms of schizophrenia. Psychopharmacol Bull. 1989;25:159-163.
44. Harvey PD, Koren D, Reichenberg A, Bowie CR. Negative symptoms and cognitive deficits: what is the nature of their relationship? Schizophr Bull. 2006;32:250-258.
45. Buchanan RW, Carpenter WT. Domains of psychopathology: an approach to the reduction of heterogeneity in schizophrenia. J Nerv Ment Dis. 1994;182:193-204.
46. McAdams LA, Harris MJ, Heaton SC, Bailey A, Fell R, Jeste DV. Validity of specific subscales of the positive and negative symptom scales in older schizophrenia outpatients. Schizophr Res. 1997;27:219-226.
47. Peralta V, Cuesta MJ. Dimensional structure of psychotic symptoms: an item-level analysis of SAPS and SANS symptoms in psychotic disorders. Schizophr Res. 1999;38:13-26.
48. Kulhara P, Avasthi A. Influence of depressive symptoms and premorbid adjustment on factor structure of phenomenology of schizophrenia: a study from India. Eur Psychiatry. 2003;18:226-232.
49. Raskin A, Pelchat R, Sood R, Alphs LD, Levine J. Negative symptom assessment of chronic schizophrenia patients. Schizophr Bull. 1993;19:627-635.
50. Kirkpatrick B. ISCTM Satellite Meeting on the NIMH Initiative Regarding Treatment Development for Negative Symptom; January 2006; Washington, DC.
51. Arango C, Buchanan RW, Kirkpatrick B, Carpenter WT. The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms. Eur Psychiatry. 2004;19:21-26.
52. Bodkin JA, Siris SG, Bermanzohn PC, Hennen J, Cole JO. Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia. Am J Psychiatry. 2005;162:388-390.
53. Buchanan RW, Ball MP, Weiner E, et al. Olanzapine treatment of residual positive and negative symptoms. Am J Psychiatry. 2005;162:124-129.
54. Laughren T, Levin R. Food and drug administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim. Schizophr Bull. 2006;32:220-222.
55. Alphs L. An industry perspective on the NIMH consensus statement on negative symptoms. Schizophr Bull. 2006;32:225-230.
56. Kane J. Commentary: consensus statement on negative symptoms. Schizophr Bull. 2006;32:223-224.
57. Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry. 1998;155:751-760.
58. Kopelowicz A, Zarate R, Tripodis K, Gonzalez V, Mintz J. Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. Am J Psychiatry. 2000;157:987-993.
59. Goff DC, Tsai G, Levitt J, et al. A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 1999;56:21-27.
60. Evins AE, Amico E, Posever TA, Toker R, Goff DC. D-cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr Res. 2002;56:19-23.
61. Duncan EJ, Szilagyi S, Schwartz MP, et al. Effects of D-cycloserine on negative symptoms in schizophrenia. Schizophr Res. 2004;71:239-248.
62. Paillère-Martinot ML, Lecrubier Y, Martinot JL, Aubin F. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry. 1995;152:130-134.
63. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
64. Loo H, Poirier-Littre MF, Theron M, Rein W, Fleurot O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry. 1997;170:18-22.
65. Danion JM, Rein W, Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am J Psychiatry. 1999;156:610-616.
66. Speller JC, Barnes TR, Curson DA, Pantelis C, Alberts JL. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol. Br J Psychiatry. 1997;171:564-568.
67. Krawiecka M, Goldberg D, Vaughan M. A standardized psychiatric assessment scale for rating chronic psychotic patients. Acta Psychiatr Scand. 1977;55:299-308.
68. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry. 1999;56:29-36.
69. Buchanan RW, Javitt DC, Marder SR, et al. Glutamatergic Agents for Treatment of Negative Symptoms and Cognitive Impairments in Patients with Schizophrenia. Atlanta, GA: SOBP; 2005.
70. Greenwood KE, Landau S, Wykes T. Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy. Schizophr Bull. 2005;31:910-921.
71. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321-330.
72. Buchanan RW, Davis M, Goff D, et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull. 2005;31:5-19.